Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 413

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 413
---
RISK
FACTORS

Investing
in shares of our common stock is very speculative and involves a high degree of risk. You should carefully consider the risks
and uncertainties described below, the section of this Annual Report entitled “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and our financial statements and related notes included elsewhere in this Annual Report. The
risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or
that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our
business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline, and
you could lose part or all of your investment.

Summary
Risk Factors

Our
business is subject to numerous risks and uncertainties that you should consider before investing in our company. You should carefully
consider all of the risks described more fully in the section titled “Risk Factors” in this Annual Report on page 19,
before deciding to invest in our common stock. If any of these risks actually occurs, our business, financial condition and results of
operations would likely be materially adversely affected. 

19

Important
factors that could cause actual results or events to differ materially, but are not limited to, the following:

Risks
Related to Our Intellectual Property

We
depend on rights to Telomir-1 that are or will be licensed to us.

We
may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.

If
third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual
property, our operating profits could be adversely affected.

We
have been granted a license to the right to develop Telomir-1 in the United States in human and pet application, but we have not been
granted a license to the rights to patents covering Telomir-1 in foreign jurisdictions.

Risks
Related to Our Operations and Financial Condition

We
are an early development-stage company with no revenues and our financial condition raises substantial
doubt as to our ability to continue as a going concern.

Because
we have a limited operating history, you may not be able to accurately evaluate our operations.

We
will need to raise additional financing for the continuation of our operations.

Our
operating results may fluctuate, which could have a negative impact on our